Souhaitez-vous accéder aux communiqués récents ?

Longeveron Chief Science Officer and Chief Medical Officer selected as speakers at the Global CardioVascular Clinical Trialists (CVCT) Forum (Dec 8-10).

Longeveron granted Canadian patent for method of using stem cells to treat patients with aging-related frailty and also for the treatment of NIDCM.

Longeveron presents new MRI biomarker data linking neuroinflammation to clinical outcomes in patients with mild Alzheimer's disease at CTAD 2025.

Cellular therapy laromestrocel Phase 2 clinical trial data in Alzheimer's disease selected for poster presentation at CTAD 2025.

Longeveron issued US patent for method of treating aging-related frailty in patients with inflammaging using its proprietary stem cell therapy.

On track for top-line trial results in the third quarter of 2026 from pivotal Phase 2b clinical trial ELPIS II. ELPIS II is evaluating laromestrocel as a potential adjunct treatment for HLHS, a rare...

Longeveron to report 3Q25 financial results and host investor/analyst call/webcast on Tuesday, November 4, 2025 after close of US financial markets.

Dr. Joshua Hare, CSO and Exec Chairman interviewed on NPR's BioTech Nation, discussing potential breakthrough stem cell therapy for HLHS.

Longeveron will participate in the 4th Annual ROTH Healthcare Opportunities Conference October 9, 2025 in New York City.

George Paletta, Jr., MD, MBA, Internationally Acclaimed Entrepreneur, Investor and Surgeon, Elected to Longeveron® Board of Directors.